NEW YORK, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies Inc. (Nasdaq:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced that management will present at the 36th Annual J.P. Morgan Healthcare Conference, to be held Jan. 8-11, 2018, in San Francisco, Calif.

36th Annual J.P. Morgan Healthcare Conference
Presentation date / time: Thursday, Jan. 11, 2018, 8:30 a.m. PST

A live webcast of the presentation will be available in the “Investors” section of the Tyme website, www.tymeinc.com/investors. The webcast will be archived on the Company’s website for 30 days following the presentation.

About Tyme

Tyme Technologies Inc. is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. Tyme’s lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer. The Company is preparing to initiate an additional Phase II clinical trial in pancreatic cancer in early 2018.

For more information, visit www.tymeinc.com.

Contacts

Tyme Inc.
Jonathan Eckard
Chief Scientific Affairs Officer
jon.eckard@tymeinc.com

ICR Healthcare
Investors
Stephanie Carrington
Stephanie.Carrington@icrinc.com
646-277-1282

6 Degrees
Media
Sarah Hall
shall@6degreespr.com
215-313-5638